OBJECTIVE： To investigate clinical efficacy and safety of Fluticasone furoate nasal spray in the treatment of allergic rhinitis （AR）. METHODS： 100 AR patients in our hospital during Jan. 2014-Dec. 2015 were divided into control group and observation group according to random number table， with 50 cases in each group. Both groups received decongestant Oxymetazoline hydrochloride spray. Control group was additionally given Budesonide spray， once each nostril on the first day， twice each nostril on the second day， increasing suitably according to disease condition， less than 6 times a day for patients younger than 14 years old， less than 8 times a day for patients older than 14 years old； observation group was additionally given Fluticasone furoate nasal spray， once each nostril， qd for patients younger than 14 years old， once each nostril， while morning and night for patients older than 14 years old. Both groups received treatment for consecutive 30 d. The total nasal symptoms score （TNSS）， total eye symptoms score （TESS）， total nasal resistance （TNR） under 75， 150 Pa， nasal minimum cross-sectional area （MCA） and the occurrence of ADR were compared between 2 groups before and after treatment. RESULTS： There was no statistical significance in above indexes between 2 groups before treatment （P＞0.05）. After treatment， TNSS of 2 groups and TESS of observation group were decreased significantly compared to before treatment， and TESS of observation group was significantly lower than that of control group， with statistical significance （P＜0.05）. There was no statistical significance in TESS of control group before and after treatment （P＞0.05）. TNR of 2 groups under 75， 150 Pa were significantly lower than before treatment， and the observation group was lower than the control group， with statistical significance （P＜0.05）. MCA of 2 groups were significantly lower than before treatment， without statistical significance between 2 groups （P＞0.05）. The incidence of ADR in observation group was significantly lower than control group， with statistical significance （P＜0.05）. CONCLUSIONS： Fluticasone furoate is similar to budesonide in the treatment of nasal symptoms of AR patients， but it is better than budesonide in improving eye symptoms and nasal ventilation function with milder ADR.